Guilin Sanjin Pharmaceutical Valuation

Q: What is the Fair Price of 2275 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

002275 (CN¥14.3) is trading below our estimate of [[fair value]] (CN¥21.5)

Is 2275 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2275 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002275 (CN¥14.3) is trading below our estimate of fair value (CN¥21.5)

Significantly Below Fair Value: 002275 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2275?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 2275. This is calculated by dividing 2275's market cap by their current preferred multiple.
What is 2275's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CN¥8.40b

2275 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.9x
Enterprise Value/EBITDA	14.4x
PEG Ratio	0.7x

Price to Earnings Ratio vs Peers

How does 2275's PE Ratio compare to its peers?

The above table shows the PE ratio for 2275 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	15.8x
000915 Shandong Wit Dyne HealthLtd	14.2x	13.6%	CN¥8.4b
600976 Jianmin Pharmaceutical GroupLtd	16.5x	20.7%	CN¥8.6b
600664 Harbin Pharmaceutical Group	17.4x	n/a	CN¥7.8b
605507 Guobang Pharma	15x	35.2%	CN¥9.3b
002275 Guilin Sanjin Pharmaceutical	23.9x	34.1%	CN¥8.4b

Price-To-Earnings vs Peers: 002275 is expensive based on its Price-To-Earnings Ratio (23.9x) compared to the peer average (15.8x).

Price to Earnings Ratio vs Industry

How does 2275's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.6%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.6%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 002275 is good value based on its Price-To-Earnings Ratio (23.9x) compared to the CN Pharmaceuticals industry average (31.3x).

Price to Earnings Ratio vs Fair Ratio

What is 2275's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2275 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	23.9x
Fair PE Ratio	33.7x

Price-To-Earnings vs Fair Ratio: 002275 is good value based on its Price-To-Earnings Ratio (23.9x) compared to the estimated Fair Price-To-Earnings Ratio (33.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.